# US 2026/0091017 A1 · Treatments for inflammation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091017 A1
- Document ID: US20260091017A1
- Status: Published application
- Kind: A1
- Application number: 19/342,361
- Filed: 2025-09-26
- Published: 2026-04-02
- Earliest claimed: 2024-09-27
- Assignees: Auckland Uniservices Limited
- Applicants: Auckland Uniservices Limited
- Inventors: AVIK SHOME; ODUNAYO OMOLOLA MUGISHO; ILVA D. RUPENTHAL
- Web page: https://patentgrep.com/patent/US20260091017A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The inventions relate to compounds, compositions and kits comprising connexin hemichannel modulators, inflammasome modulators, and/or pannexin channel modulators and new and improved methods comprising systemic and topical administration of such modulators for the treatment of ocular and dermatological diseases, disorders and conditions, including ocular and dermatological diseases, disorders and conditions characterized at least in part by inflammasome-mediated inflammationb.

## Claims

### Claim 1

A method for treating a subject having a disease, disorder or condition characterized at least in part by inflammation, comprising (a) systemically administering to the subject an inflammasome modulator, and (b) topically administering to the subject an inflammasome modulator, wherein inflammation is reduced.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the inflammation is ocular.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the systemically administered inflammasome modulator is an inflammasome modulator, e.g., an NLRP3 inflammasome modulator.

### Claim 4 (depends on 1)

A method according to claim 1, wherein the topically administered inflammasome modulator is an inflammasome modulator, e.g., an NLRP3 inflammasome modulator.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the systemically administered inflammasome modulator is connexin 43 hemichannel modulator.

### Claim 6 (depends on 1)

A method according to claim 1, wherein the topically administered inflammasome modulator is connexin 43 hemichannel modulator.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the systemically administered inflammasome modulator is administered orally.

### Claim 8 (depends on 1)

A method according to claim 1, wherein the disease, disorder or condition is characterized at least in part by ocular inflammation.

### Claim 9 (depends on 1)

A method according to claim 1, wherein the disease, disorder or condition is characterized at least in part by anterior ocular inflammation.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the disease, disorder or condition is characterized at least in part by posterior ocular inflammation.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the disease, disorder or condition is characterized at least in part by posterior retinal inflammation.

### Claim 12 (depends on 1)

A method according to claim 1, wherein the inflammation is dermal.

### Claim 13 (depends on 1)

A method according to claim 1, wherein the disease, disorder or condition is characterized at least in part by dermal inflammation.

### Claim 14 (depends on 1)

A method according to claim 1, wherein the NLRP3 inflammasome inhibits release of ATP from connexin 43 hemichannels.

### Claim 15 (depends on 5)

A method according to claim 5, wherein that connexin hemichannel modulator inhibits NLRP3 inflammasome activity.

### Claim 16 (depends on 6)

A method according to claim 6, wherein that connexin hemichannel modulator inhibits NLRP3 inflammasome activity.

### Claim 17 (depends on 1)

The method of claim 1, wherein the disease, disorder or condition is noninfectious uveitis.

### Claim 18 (depends on 1)

The method of claim 1, wherein the disease, disorder or condition is infectious uveitis.

### Claim 19 (depends on 1)

The method of claim 1, wherein the disease, disorder or condition is infectious uveitis -related macular edema.

### Claim 20 (depends on 17)

The method of claim 17, further comprising the administration of a corticosteroid.

### Claim 21 (depends on 20)

The method of claim 20, wherein the corticosteroid is administered systemically, topically, by intraocular injection or by ocular implant.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the corticosteroid is selected from the group consisting of prednisolone, dexamethasone, difluprednate, loteprednol and fluorometholone.

### Claim 23 (depends on 18)

The method of claim 18, further comprising the administration of at least one antimicrobial agent.

### Claim 24 (depends on 1)

The method of claim 1, wherein the disease, disorder or condition is diabetic macular edema.

### Claim 25 (depends on 1)

The method of claim 1, wherein the disease, disorder or condition is diabetic retinopathy.

### Claim 26 (depends on 1)

The method of claim 1, wherein the inflammasome modulator is a connexin hemichannel modulator compound according to Formula I.

### Claim 27 (depends on 26)

The method of claim 26, wherein the connexin hemichannel modulator is a compound according to Formula I is tonabersat.

### Claim 28 (depends on 27)

The method of claim 27, wherein tonabersat is administered orally and topically and the subject is a human.

### Claim 29 (depends on 1)

The method of claim 1, wherein the connexin hemichannel modulator is a compound is a tonabersat prodrug.

### Claim 30 (depends on 29)

The method of claim 29, wherein the tonabersat prodrug is a compound according to Formula II.

### Claim 31 (depends on 1)

The method of claim 1, wherein the systemically administered inflammasome modulator is administered at least once per day.

### Claim 32 (depends on 1)

The method of claim 1, wherein the topically administered inflammasome modulator is administered at least once per day.

### Claim 33 (depends on 1)

The method of claim 1, wherein the inflammasome modulator is tonabersat and it is administered in an amount ranging from about 20 mg to 120 mg per dose.

### Claim 34 (depends on 33)

The method of claim 33, wherein is administered in an amount ranging from about 30 mg to 90 mg per dose.

### Claim 35 (depends on 1)

The method of claim 1, where the subject is a human.
